PDCD1 and pancreatic neoplasm: These outcomes could partly explain chemotherapy with checkpoint inhibitory drugs such as PD-1/PD-L1 inhibitors showing modest benefit in clinical trials, and TIGIT inhibitors may be more proper as alternative immunotherapy for pancreatic cancer.